18th Jul 2008 07:00
CELSIS INTERNATIONAL PLC
("Celsis", "the Company" or "the Group")
Annual Information update
18 July 2008: Celsis International plc, the international life sciences products and laboratory services company, is pleased to provide an annual information update, in accordance with the requirements of the Prospectus Rule 5.2. This update refers to information that has been published or made available by the Company to the public over the twelve months preceding this announcement. To avoid a statement of unnecessary length information is referred to in this update rather than included in full.
In accordance with Rule 5.2.7 of the Prospectus Rules, the information referred to in this update was up to date at the time the information was published but some information may now be out of date. This annual information update does not constitute an offer of securities addressed to any person and should not be relied on by any person.
1. Announcements made via the Regulatory News Service ("RNS"), a Regulatory Information Service ("RIS").
|
Date of Publication |
Regulatory Headline |
|
3 July 2008 |
Annual Report and Accounts |
|
18 June 2008 |
Final Results |
|
2 June 2008 |
Notice of Results |
|
28 May 2008 |
Holding(s) in Company |
|
24 April 2008 |
Holding(s) in Company |
|
7 April 2008 |
Holding(s) in Company |
|
7 April 2008 |
Holding(s) in Company |
|
27 March 2008 |
Agreement |
|
27 March 2008 |
Pre Close Trading Update |
|
7 February 2008 |
Interim Management Statement |
|
5 February 2008 |
Holding(s) in Company |
|
16 January 2008 |
Director/PDMR Shareholding |
|
7 January 2008 |
Holding(s) in Company |
|
7 January 2008 |
Holding(s) in Company |
|
3 January 2008 |
Holding(s) in Company |
|
2 January 2008 |
Holding(s) in Company |
|
20 December 2007 |
Holding(s) in Company |
|
31 October 2007 |
Interim Results |
|
9 October 2007 |
Notice of Results |
|
27 September 2007 |
Pre Close Trading Update |
|
24 September 2007 |
Holding(s) in Company |
|
7 September 2007 |
Holding(s) in Company |
|
29 August 2007 |
Director/PDMR Shareholding |
|
14 August 2007 |
Interim Management Statement |
|
31 July 2007 |
Director/PDMR Shareholding |
|
26 July 2007 |
AGM Result |
|
26 July 2007 |
AGM Statement |
|
18 July 2007 |
Annual Information Update |
Copies of all announcements can be obtained from the Regulatory News Service of the London Stock Exchange.
2. Documents filed at Companies House
The documents listed below were filed with the Registrar of Companies in England and Wales on or around the dates indicated. Copies of these documents can be obtained from Companies House.
|
Date |
Document type |
Description |
|
26 September 2007 |
AA |
Report and Accounts |
|
11 September 2007 |
363 |
Annual Return |
|
21 August 2007 |
288b |
Director Resigned |
|
24 July 2007 |
287 |
Registered office change |
3. Documents sent to Shareholders
The documents listed below have been despatched by the Company to holders of its securities on or around the following dates.
|
Date |
Description |
|
30 June 2008 |
2008 Annual Report and Accounts |
|
30 June 2008 |
Notice of Annual General Meeting |
|
14 May 2008 |
Deemed Consent Letter |
|
5 December 2007 |
2007 Interim Report |
4. Documents submitted to the UK Listing Authority
Copies of the following documents have been submitted to the UK Listing Authority for inspection at their Document Viewing Facility on or around the following dates and can be obtained from the Company Secretary, Celsis International plc, 1010 Cambourne Business Park, Cambourne, Cambridge, CB23 6DP.
|
Date |
Description |
|
30 June 2008 |
2008 Annual Report and Accounts |
|
30 June 2008 |
Notice of Annual General Meeting |
|
5 December 2007 |
2007 Interim Report |
|
Enquiries: |
|
|
Celsis International plc |
Tel: +44 (0) 1223 598 428 |
|
Christian Madrolle, Company Secretary |
|
|
Jenny Woolway, Corporate Communications |
|
|
Financial Dynamics |
Tel: +44 (0) 20 7831 3113 |
|
David Yates |
|
|
Jonathan Birt |
Notes to editors
Celsis International plc
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange (CEL.L).
Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market.
Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry and biological sciences to stability storage and testing.
Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical industry. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly metabolised by the human liver.
Further information can be found on its website at www.celsis.com.
Related Shares:
Celadon Pharmaceuticals